GSK sales in China tumble amid probe

GLAXOSMITHKLINE says its sales of drugs and vaccines in China have tumbled in the third quarter as it was hit by bribery investigations there.

Worldwide sales, it says, were flat as growth in the US and Europe helped offset China's 61 per cent drop. Total revenue rose one per cent to STG6.51 billion ($A10.95 billion).

The company was hit by allegations by the Chinese government that four of its employees paid bribes to doctors and hospitals to encourage them to prescribe medications.

Chief Executive Andrew Witty said on Wednesday that the decline in China was disappointing but it was too early to judge the long-term impact of the probe.

The company says it expects earnings per share to grow between three per cent and four per cent this year.

Anda sedang membaca artikel tentang

GSK sales in China tumble amid probe

Dengan url

https://tikusinternet.blogspot.com/2013/10/gsk-sales-in-china-tumble-amid-probe.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

GSK sales in China tumble amid probe

namun jangan lupa untuk meletakkan link

GSK sales in China tumble amid probe

sebagai sumbernya